IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.169
AS - Asia 1.603
EU - Europa 754
SA - Sud America 272
AF - Africa 55
OC - Oceania 3
Totale 4.856
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.110
SG - Singapore 784
CN - Cina 320
BR - Brasile 216
HK - Hong Kong 181
IT - Italia 155
VN - Vietnam 103
DE - Germania 100
RU - Federazione Russa 96
FR - Francia 90
GB - Regno Unito 56
IN - India 55
IE - Irlanda 48
FI - Finlandia 46
KR - Corea 39
CA - Canada 31
NL - Olanda 28
MX - Messico 23
BD - Bangladesh 22
UA - Ucraina 22
AR - Argentina 20
AT - Austria 20
TR - Turchia 17
CH - Svizzera 16
ES - Italia 16
TG - Togo 15
PL - Polonia 14
SE - Svezia 14
CZ - Repubblica Ceca 12
JP - Giappone 12
ID - Indonesia 9
PK - Pakistan 9
ZA - Sudafrica 9
CO - Colombia 8
EC - Ecuador 8
SA - Arabia Saudita 8
IQ - Iraq 7
TN - Tunisia 7
MA - Marocco 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
VE - Venezuela 5
KE - Kenya 4
LT - Lituania 4
PE - Perù 4
AU - Australia 3
BE - Belgio 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
JO - Giordania 3
OM - Oman 3
RO - Romania 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
KZ - Kazakistan 2
NP - Nepal 2
PH - Filippine 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DM - Dominica 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
MT - Malta 1
MY - Malesia 1
MZ - Mozambico 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 4.856
Salva come PNG Salva come JPEG
Città #
Singapore 334
Ashburn 274
Hong Kong 179
San Jose 133
Beijing 129
Chicago 125
Los Angeles 125
Boardman 75
Fairfield 69
Chandler 68
Council Bluffs 62
Salt Lake City 57
Lauterbourg 56
Dallas 52
Dublin 47
Houston 42
Hefei 40
Munich 40
Seoul 39
Wilmington 39
Woodbridge 38
New York 34
Cambridge 32
Elk Grove Village 30
Ho Chi Minh City 30
Seattle 30
Hanoi 28
Buffalo 25
Frankfurt am Main 24
Redondo Beach 24
Santa Clara 24
Tampa 23
Helsinki 22
The Dalles 22
São Paulo 20
Montreal 19
London 17
Nuremberg 17
Zurich 16
Lomé 15
Ann Arbor 14
Miami 14
Dearborn 13
Denver 13
Orem 13
Pune 13
Turku 13
Vienna 13
Genoa 12
Ogden 12
Warsaw 12
Amsterdam 11
Tokyo 11
Brno 10
Chennai 10
Stockholm 10
Milan 9
Princeton 9
Sterling 9
Arezzo 8
Brooklyn 8
Dulles 8
Hyderabad 8
Lappeenranta 8
Phoenix 8
Redmond 8
Rome 8
Mumbai 7
Poplar 7
Udine 7
Ankara 6
Jacksonville 6
Manchester 6
Mexico City 6
Portsmouth 6
Shanghai 6
Shenzhen 6
Belluno 5
Belo Horizonte 5
Des Moines 5
Detroit 5
Düsseldorf 5
Guangzhou 5
Guarulhos 5
Guayaquil 5
Haiphong 5
Lancaster 5
Madrid 5
Naples 5
New Delhi 5
Rio de Janeiro 5
Tunis 5
Atlanta 4
Boston 4
Brasília 4
Cormons 4
Da Nang 4
Deiva Marina 4
Hải Dương 4
Izmir 4
Totale 2.930
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 547
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 174
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 145
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 138
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 124
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 118
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 114
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 112
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 112
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 109
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 104
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 102
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 98
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 98
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 97
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 94
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 90
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 90
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 86
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 86
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 82
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 80
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 75
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 74
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 73
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 73
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 72
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 71
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 71
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 67
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 67
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 67
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 67
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 66
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 66
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 66
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 65
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 65
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 62
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 62
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 62
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 61
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 60
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 60
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 59
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 59
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 58
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 56
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 52
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 52
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 52
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 49
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 48
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 47
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 44
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 43
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 41
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 38
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 34
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 26
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 19
Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence 13
Editorial: Innovations in pharmacogenomics: embracing diversity and clinical application 4
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 3
Totale 5.069
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 5 7 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20262.756 456 408 403 223 320 206 307 95 164 174 0 0
Totale 5.069